TRTabea V. Riepe

Tabea V. Riepe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tabea V. Riepe has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-Cell Nanomotion and Machine Learning for Parallel Bacterial Identification and Antibiotic Screening

    by Santiago Mendoza-Silva, Farbod Alijani, Le-Vaughn Naarden, Roxan Broer, Leo Smeets, Tabea Riepe, Irek E. Roslon, Aleksandre Japaridze

    Rapid and accurate identification of bacterial infections and their resistance to antibiotics is critical to effective clinical decision-making and combating antimicrobial resistance. However, current diagnostic approaches are typically segmented: techniques such as MALDI-TOF provide species identification, but cannot assess antibiotic susceptibility, while standard antimicrobial susceptibility (AST) tests are time-consuming and lack concurrent identification capability. In this study, we overcome these limitations by integrating single-cell nanomotion detection using graphene drums with machine learning (ML) algorithms to perform both tasks simultaneously within a single measurement. Nanomotion signals, nanoscale vibrations from single living cells, are recorded in real-time and transformed into time-frequency spectrograms, which serve as inputs to ML models trained for robust pattern recognition. Our framework enables the differentiation of Escherichia coli, Staphylococcus aureus , and Klebsiella pneumoniae , while simultaneously distinguishing resistant and susceptible strains with 98% precision. By coupling highly-sensitive graphene nanomotion sensors with advanced ML tools, our approach delivers a label-free bacterial diagnostics, offering both identification and susceptibility profiling at the single-cell level within a couple of hours.

  • Open Access

    Deciphering the largest disease-associated transcript isoforms in the human neural retina with advanced long-read sequencing approaches

    by Merel Stemerdink, Tabea Riepe, Nick Zomer, Renee Salz, Michael Kwint, Jaap Oostrik, Raoul Timmermans, Barbara Ferrari, Stefano Ferrari, Alfredo Dueñas Rey, et al.

    Sequencing technologies have long limited the comprehensive investigation of large transcripts associated with inherited retinal diseases (IRDs) like Usher syndrome, which involves 11 associated genes with transcripts up to 19.6 kb. To address this, we used PacBio long-read mRNA isoform sequencing (Iso-Seq) following standard library preparation and an optimized workflow to enrich for long transcripts in the human neural retina. While our workflow achieved sequencing of transcripts up to 15 kb, this was insufficient for Usher syndrome–associated genes USH2A and ADGRV1 , with transcripts of 18.9 kb and 19.6 kb, respectively. To overcome this, we employed the Samplix Xdrop System for indirect target enrichment of cDNA, a technique typically used for genomic DNA capture. This method facilitated the successful capture and sequencing of ADGRV1 transcripts as well as full-length 18.9 kb USH2A transcripts. By combining algorithmic analysis with detailed manual curation of sequenced reads, we identified novel isoforms characterized by an alternative 5′ transcription start site, the inclusion of previously unannotated exons, or alternative splicing events across the 11 Usher syndrome–associated genes. These findings have significant implications for genetic diagnostics and therapeutic development. The analysis applied here on Usher syndrome–associated transcripts exemplifies a valuable approach that can be extended to explore the transcriptomic complexity of other IRD-associated genes in the complete transcriptome data set generated within this study. Additionally, we demonstrate the adaptability of the Samplix Xdrop System for capturing cDNA, and the optimized methodologies described can be expanded to facilitate the enrichment of large transcripts from various tissues of interest.


  • Open Access

    Deep learning-based prediction of tissue-specific splice sites in the human neural retina

    by Tabea V. Riepe, Suzanne E. de Bruijn, Susanne Roosing, Frans P.M. Cremers, Peter A.C. ‘T Hoen

    Splice prediction tools can be used to identify splice-altering variants in patients with inherited diseases. Since splicing is tissue-specific, a predicted splice defect may vary depending on the tissue of interest. Current splice prediction tools often neglect splice junctions from the human neural retina, which can lead to the misinterpretation of benign and pathogenic variants in patients with inherited retinal diseases (IRDs). To address this issue, we developed a retina-specific splice prediction tool based on the model architecture of SpliceAI. In addition to retraining the existing model using splice junctions derived from retina RNA-sequencing data, we also improved the model’s generalization through hyperparameter optimizations such as dropout. The resulting retina-specific model was validated on retina-enriched exons and variants known to cause retina-specific splicing defects. Although the retina model correctly identified five more retina-enriched splice sites than the GTEx model, it did not enhance predictions for variants with tissue-specific splicing defects nor did it identify novel pathogenic variants in a set of genetically unexplained IRD cases. Despite these limitations, the retina-specific SpliceAI model shows promising results and should be applied to a larger patient cohort to uncover novel splice-altering variants in IRD patients.

  • Open Access

    Pushing the limits of single molecule transcript sequencing to uncover the largest disease-associated transcript isoforms in the human neural retina

    by Merel Stemerdink, Tabea Riepe, Nick Zomer, Renee Salz, Michael Kwint, Raoul Timmermans, Barbara Ferrari, Stefano Ferrari, Alfredo Dueñas Rey, Emma Delanote, et al.

    Sequencing technologies have long limited the comprehensive investigation of large transcripts associated with inherited retinal diseases (IRDs) like Usher syndrome, which involves 11 associated genes with transcripts up to 19.6 kb. To address this, we used PacBio long-read mRNA isoform sequencing (Iso-Seq) following standard library preparation and an optimized workflow to enrich for long transcripts in the human neural retina. While our workflow achieved sequencing of transcripts up to 15 kb, this was insufficient for Usher syndrome-associated genes USH2A and ADGRV1 , with transcripts of 18.9 kb and 19.6 kb, respectively. To overcome this, we employed the Samplix Xdrop System for indirect target enrichment of cDNA, a technique typically used for genomic DNA capture. This method facilitated the successful capture and sequencing of ADGRV1 transcripts as well as the full-length 18.9 kb USH2A transcripts. By combining algorithmic analysis with detailed manual curation of sequenced reads, we identified novel isoforms and alternative splicing events across the 11 Usher syndrome-associated genes, with implications for diagnostics and therapy development. Our findings demonstrate the Xdrop system’s adaptability for cDNA capture and the advantages of integrating computational and manual transcript analyses. The full neural retina sequencing dataset is available via EGA under identifier EGAD50000000720.

  • Open Access

    A proteogenomic atlas of the human neural retina

    by Tabea V. Riepe, Merel Stemerdink, Renee Salz, Alfredo Duenas Rey, Suzanne E. de Bruijn, Erica Boonen, Tomasz Z. Tomkiewicz, Michael Kwint, Jolein Gloerich, Hans J.C.T. Wessels, et al.

    The human neural retina is a complex tissue with abundant alternative splicing and more than 10% of genetic variants linked to inherited retinal diseases (IRDs) alter splicing. Traditional short-read RNA-sequencing methods have been used for understanding retina-specific splicing but have limitations in detailing transcript isoforms. To address this, we generated a proteogenomic atlas that combines PacBio long-read RNA-sequencing data with mass spectrometry and whole genome sequencing data of three healthy human neural retina samples. We identified nearly 60,000 transcript isoforms, of which approximately one-third are novel. Additionally, ten novel peptides confirmed novel transcript isoforms. For instance, we identified a novel IMPDH1 isoform with a novel combination of known exons that is supported by peptide evidence. Our research underscores the potential of in-depth tissue-specific transcriptomic analysis to enhance our grasp of tissue-specific alternative splicing. The data underlying the proteogenomic atlas are available via EGA with identifier EGAD50000000101, via ProteomeXchange with identifier PXD045187, and accessible through the UCSC genome browser.


  • Open Access

    Benchmarking deep learning splice prediction tools using functional splice assays

    by Tabea V. Riepe, Mubeen Khan, Susanne Roosing, Frans P. M. Cremers, Peter A. C. 'T Hoen

    Hereditary disorders are frequently caused by genetic variants that affect pre‐mRNA splicing. Whilst genetic variants in the canonical splice motifs are almost always disrupting splicing, the pathogenicity of variants in the non‐canonical splice sites (NCSS) and deep intronic (DI) regions are difficult to predict. Multiple splice prediction tools have been developed for this purpose, with the latest tools employing deep learning algorithms. We benchmarked established and deep learning splice prediction tools on published gold standard sets of 71 NCSS and 81 DI variants in the ABCA4 gene and 61 NCSS variants in the MYBPC3 gene with functional assessment in midigene and minigene splice assays. The selection of splice prediction tools included CADD, DSSP, GeneSplicer, MaxEntScan, MMSplice, MTSplice, NNSPLICE, SPIDEX, SpliceAI, SpliceRover and SpliceSiteFinder‐like. The best performing splice prediction tool for the different variants was SpliceRover for ABCA4 NCSS variants, SpliceAI for ABCA4 DI variants and SpliceSiteFinder‐like for NCSS variants in MYBPC3. Overall, the performance in a real time clinical setting is much more modest than reported by the developers of the tools.